Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines
Metrics: PDF 481 views | HTML 1138 views | ?
Nachi Namatame1,2, Naomi Tamaki1, Yuya Yoshizawa1, Mutsumi Okamura1, Yumiko Nishimura1, Kanami Yamazaki1, Miwa Tanaka3, Takuro Nakamura3, Kentaro Semba4, Takao Yamori1,5, Shin-ichi Yaguchi1,2 and Shingo Dan1
1Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan
2R&D Center, Zenyaku Kogyo Co. Ltd, Tokyo, Japan
3Division of Carcinogenesis, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
4Department of Life Science and Medical Bioscience, School of Advanced Science and Engineering, Waseda University, Tokyo, Japan
5Present address: Center for Product Evaluation, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan
Shingo Dan, email: email@example.com
Keywords: sarcoma; PI3K; anticancer agent; cell line panel; oncogenic chromosomal translocation
Received: April 10, 2018 Accepted: September 26, 2018 Published: October 12, 2018
Treatment of patients with advanced sarcoma remains challenging due to lack of effective medicine, with the development of novel drugs being of keen interest. A pan-PI3K inhibitor, ZSTK474, has been evaluated in clinical trials against a range of advanced solid tumors, with clinical benefit shown in sarcoma patients. In the present study, we developed a panel of 14 human sarcoma cell lines and investigated the antitumor effect of 24 anticancer agents including ZSTK474, other PI3K inhibitors, and those clinically used for sarcoma treatment. ZSTK474 exhibited a similar antiproliferative profile to other PI3K inhibitors but was clearly different from the other drugs examined. Indeed, ZSTK474 inhibited PI3K-downstream pathways, in parallel to growth inhibition, in all cell lines examined, showing proof-of-concept of PI3K inhibition. In addition, ZSTK474 induced apoptosis selectively in Ewing’s sarcoma (RD-ES and A673), alveolar rhabdomyosarcoma (SJCRH30) and synovial sarcoma (SYO-1, Aska-SS and Yamato-SS) cell lines, all of which harbor chromosomal translocation and resulting oncogenic fusion genes, EWSR1-FLI1, PAX3-FOXO1 and SS18-SSX, respectively. Finally, animal experiments confirmed the antitumor activity of ZSTK474 in vivo, with superior efficacy observed in translocation-positive cells. These results suggest that ZSTK474 could be a promising drug candidate for treating sarcomas, especially those harboring chromosomal translocation.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.